Christine Powell

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

Susan Quinn, Revathi Ananthakrishnan, Thomas J Lynch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Yan Sun, Luc Y Dirix, Zefei Jiang, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.